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Summary This study evaluated the preclinical activity and
molecular predictors of response to gefitinib (Iressa®, Astra
Zeneca Inc, UK) in nasopharyngeal carcinoma (NPC). The
activity of gefitinib was evaluated in four human NPC cell
lines—HK1, HONE-1, CNE2, C666-1. A representative
gefitinib-sensitive (HK1, IC50=250 nM) and gefitinib-
resistant cell line (HONE-1, IC50>15 μM) were selected
and compared for expression of epidermal growth factor
receptor (EGFR) and related ligands, and activation of
downstream proteins. Gefitinib induced G1 cycle arrest,
apoptosis and inhibited cell invasion more significantly in
HK1 than HONE-1 cells. HK1 expressed higher levels of
p-EGFR, lower p-AKT and phospho-signal transducer and
activator of transcription 3 (p-STAT3) than other cell lines.
EGFR gene was found to be amplified in HK1. Gefitinib at
IC50 concentrations significantly suppressed EGF-induced
activation of p-EGFR, phospho-mitogen-activated protein
kinase (p-MAPK) and p-STAT3, but p-AKT showed
persistent activation in HK1 and HONE-1 cells. There
was no difference in EGFR-ligand expression between the
4 NPC cell lines. In NPC samples derived from non-
responders to gefitinib, 50% and 60% showed cytoplasmic
and nuclear pi-EGFR expression, respectively, and 33%
showed p-AKT expression. EGFR or KRAS mutations were
not detected. This study suggests that most NPC cell lines
are intrinsically resistant to gefitinib (except HK1 cells),
and further studies are needed to confirm whether EGFR
gene amplification and persistent AKT activation may
influence response to gefitinib in NPC.
Keywords Head and neck cancer . Gefitinib .
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Introduction
Nasopharyngeal carcinoma (NPC) is endemic to China and
the Southeast Asian region and areas like Hong Kong,
where it reaches a peak incidence rate of around 20 per
100,000 person-years [1]. Our previous work supports
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epidermal growth factor receptor (EGFR) as a potential
therapeutic target for NPC, as it is overexpressed in 80% of
NPC and represents a negative prognostic factor [2]. Based
on our work which has demonstrated the preclinical and
clinical activity of the anti-EGFR antibody, cetuximab in
NPC [3, 4] in NPC, we evaluated the EGFR tyrosine kinase
inhibitor, gefitinib (ZD1839, Iressa®, Astra Zeneca Inc,
Macclesfield, UK) in a previously reported phase II trial in
advanced NPC [5]. The objectives of the current study were
to determine the preclinical activity and molecular predic-
tors of response to gefitinib in NPC cell lines and in
primary tumor biopsies obtained from our phase II study.
These factors included the activation level of EGFR and its
downstream signaling mediators (mitogen-activated protein
kinase, MAPK; protein kinase B, AKT; signal transducer
and activator of transcription 3, STAT3); expression level of
EGFR-related ligands (epidermal growth factor, EGF;
amphiregulin; heparin-binding EGF-like growth factor,
HB-EGF; transforming growth factor alpha, TGF-α); and
the presence of any EGFR or KRAS mutations.
Method and materials
Cell culture
Analyses were carried in four human-derived NPC cell lines
(CNE-2, C666-1, HONE-1 and HK1) and the normal
nasopharyngeal epithelial cell line NP69was used as a control.
Reagents and antibodies
Gefitinib was kindly provided by Astra Zeneca Inc
(Macclesfield, UK). For in vitro experiments, the following
antibodies were purchased from Cell Signaling Technology
(Beverly, USA): anti-total EGFR, anti-phospho(p)-EGFR
(Y1068), anti-total STAT3, anti-p-STAT3 (Tyr705); anti-
total p44/42MAPK(Thr202/Tyr204), anti-p-p44/42MAPK
(Thr202/Tyr204), AKT (#9272S), anti-total AKT and p-AKT
(Ser473) (#9270S), antibody against cleaved poly(ADP-
ribose) polymerase (PARP) proteins. Anti-beta-actin antibody
was from Calbiochem, Merck (Gibbstown, USA). The
following antibodies fromCell Signaling Technology (Beverly,
USA) were used for immunohistochemistry: p-AKT (Ser473),
anti-p-EGFR (Tyr 845), and p-EGFR (Tyr 992). MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was
from Invitrogen (USA) and recombinant human EGF was
purchased from PeproTech (London, UK).
Cell viability assay
Cells were treated with increasing concentrations of gefitinib
(from 0 to 100 μM) for up to 48 hours (h) and cytotoxicity
was assessed by the MTT assay. Cells were cultured in 48-
well plates (2,500–7,000 cells/well) and then incubated with
gefitinib at 24 h for 48 to 72 h. DMSOwas used as a blanking
control. The drug concentration at which 50% of maximum
growth inhibition was achieved was determined as the IC50
using the GraphPad PRISM software (ISS, San Diego, CA).
All experiments were repeated in triplicates.
Western blot and apoptosis
Western Blot was used to detect the expression of total and
phosphorylated levels of EGFR, MAPK, STAT3 and AKT
in NPC cell lines, at basal condition and after treatment
with gefitinib at or near IC50 concentration for 48 h under
serum-starved and EGF-stimulated (20 ng/ml) conditions.
Apoptosis was determined via detection of PARP cleavage
proteins. Cell lysates were prepared as previously described
[6] and 25 µg of total protein was subjected to SDS-PAGE
and immunoblotting with specific antibodies as listed
above. Supersignal West Pico Chemiluminescence Western
blotting detection reagents (ThermoFisher Scientific, USA)
were used for signal detection by autoradiography.
RNA extraction and RT-PCR
The expression levels of EGFR-related ligands were
determined by Reverse Transcription-Polymerase Chain
Reaction (RT)-PCR. Total RNA was extracted from cell
pellets using TriReagent (Molecular Research Center, USA)
and treated with DNase by a TURBO DNA-free™ Kit
(Ambion, USA). One μg of RNA was used for reverse
transcription using the Go-Taq polymerase (Promega Co,
USA) using GAPDH as control as previously described [7].
The primers and conditions are outlined in Table A of the
section on Supplementary Material. RT-PCR products were
analyzed on a 1.8% agarose gel.
Cell cycle
Cells were plated in 100-mm2 Petri dishes (3 to 4×105) and
then treated with gefitinib for up to 24 h. Cells were
collected by trypsinization, fixed with 70% cold ethanol
and stored at −20°C. DNA staining was performed with a
solution containing RNase (0.2 mg/ml) and propidium
iodide (0.05 μg/ml). Analysis was performed using a
FACScan flow cytometer and data were processed with
CELLQuest software (Becton Dickinson Co, USA).
Matrigel invasion assay
The cell invasion assay was performed using a Matrigel
Invasion Chamber with a pore size of 8 µm (Becton
Dickinson Co, USA). Cells were seeded at a density of
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25×104 cells per well (for HONE-1 cells), or 7×104 cells
per well (for HK1 cells) in serum-free medium. The cell-
containing chamber was immersed in a lower chamber
containing either serum-free mediumwith or without gefitinib
(5 μM, 15 μM), in the presence of EGF (10 ng/ml) or DMSO.
After 24 h, non-invaded cells retained in the upper chamber
were removed and stained with 1% Toludine Blue O (Sigma,
USA) in 1% Borax (USB, USA), and then counted under the
microscope at 200 times magnification.
EGFR gene amplification
DNA copy number changes in NPC cell lines were
analyzed by Agilent Human Genome CGH Microarray
and scanned with a G2505B Agilent DNA microarray
scanner as previously described [8]. Using the CGH
Analytics Software 3.4, the array CGH data was analyzed
and genomic profile of each sample was generated. All
software and equipment used for microarray were from
Aglient Technologies (USA). Z-score algorithm was ap-
plied for calculating the chromosomal aberration, and genes
with log2 ratio greater than 1 were considered as amplified.
Immunohistochemistry
Paraffin-embedded samples of primary NPC biopsies were
obtained before treatment from 9 participants (out of a total
of 15) of a phase II trial of gefitinib in NPC [5]. This
clinical protocol was approved by the Institutional Ethics
Committee and all participants gave written informed consent.
Tissue sections of 4 μm thickness were immunostained using
the Benchmark XT immunostainer and ultraView™ detection
kit (Ventana Inc, USA). An immunostained sample of breast
cancer was used as a positive control and the negative control
was made by replacing the antibody with Tris buffered saline.
Slides were evaluated under a light microscope at 200 times
magnification by a pathologist (K.F.To). Phosphorylated-
AKT (Ser473) expression was considered positive (1+) or
negative, if nuclear staining was present or negative, respec-
tively. The expression of pi-EGFR-Y845 was scored by
estimating the proportion of tumor cells with positive nuclear
staining (negative if none; 1+, if less than or equal to 10%; 2+,
if 10–50%; 3+, if over 50%). The cytoplasmic expression of
pi-EGFR-Tyr 992 was scored as previously described [2].
Mutational analysis
Paraffin-embedded NPC samples were deparafinized and
DNA was isolated using QIAamp DNA Mini Kit (Qiagen
GmbH, Germany). Sections of 130 μm thick were cut and
dewaxed through suspension in 40 µL of TK buffer. To
inactivate the enzyme, samples were incubated at 55°C for
3 days and heated at 95°C for 10 min. One µL of protein
was used for PCR analysis, the amplicons were amplified
a b
c
Fig. 1 a Effect of gefitinib
(Iressa®, 15 μM) on apoptosis
in HONE-1 cells as indicated by
expression of cleaved PARP.
b Effect of gefitinib (Iressa®,
250 nM) on apoptosis in HK1
cells as indicated. c Gefitinib
induced G1 Arrest in HONE-1
(left) and HK1 (right) cell lines
following exposure for 24 h
at IC50 concentrations by
expression of cleaved PARP
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using AmpliTaq Gold polymerase (Applied Biosystems,
USA) and purified using the High Pure PCR Purification Kit
(Roche Diagnostics, USA). Sequencing was performed using
the dRhodamine Terminator Cycle Sequencing Kit (Perkin-
Elmer, USA) and the Applied Biosystems 310 Genetic
Analyzer. The primers and PCR conditions are outlined in
Table B of the section on Supplementary Material.
Results
Effect of gefitinib on growth, apoptosis, cell cycle
progression and cell invasion
The IC50 value for gefitinib in HK1 cells (250 nM) was the
lowest compared with the other NPC cell lines of which the
IC50 values ranged between 15–40 µM, while the IC50 for
NP69 was 28.6 μM (data was not shown). In order to
elucidate the biological characteristics associated with sensi-
tivity to gefitinib, HK1 and HONE-1 cell lines were chosen as
a representative gefitinib-sensitive and gefitinib-resistant cell
line, respectively, for all subsequent analyses described below.
When treated with gefitinib at IC50 concentrations,
apoptosis was observed in both HK1 and HONE-1 cells
after 24 to 48 h as evident by an increased expression of
cleaved PARP (Fig. 1a and b). Exposure to gefitinib at similar
concentrations also resulted in G1 cycle arrest (Fig. 1c), and
inhibition of the invasive activity of HONE-1 and HK1 cells
compared with control (Fig. 2).
Molecular profile of gefitinib-sensitive and gefitinib
insensitive cell lines
At basal condition, the level of total and p-EGFR and p-
MAPK was higher in HK1 compared to HONE-1 cells
(Fig. 3a). In contrast, the level of p-AKT and p-STAT3 were
higher in HONE-1 compared with HK1 cells, while there
were no significant differences in the levels of total AKT,
STAT3 and MAPK expression. However, such differences
were not observed under EGF-stimulated conditions
(Fig. 3b). When HK1 and HONE-2 cells were treated with
gefitinib at or near their respective IC50 concentrations, the
level of p-MAPK and p-STAT3 were significantly reduced
in both cell lines (Fig. 3c). Phosphorylated AKT expression
was significantly reduced when both cell lines were treated
with gefitinib well above the respective IC50 concentrations
(Fig. 3b). The expression level of TGF-α, EGF, HB-EGF,
amphiregulin were compared in HK1 and HONE-1 cell
lines. No difference was found in the ligand expression
level of these cell lines (Fig. 3d). Furthermore, none of the
cell lines harbored EGFR TK mutations (data not shown).
In order to explain why HK1 cells expressed such high
level of p-EGFR in the absence of EGFR activating
mutations, HK1 cells were analyzed for gene amplification
and a high level of EGFR amplification was found using
aCGH microarray platform (Fig. 4). The threshold log2
ratio of this amplicon core was around 3.
Immunohistochemistry and EGFRmutation in tumor samples
Of the pre-treatment biopsies obtained from 9 patients, only
3 samples showed mild (+1) p-AKT expression. Under half
(4/9 samples) of the samples showed EGFR overexpression
(cytoplasmic staining), while the 6 (out of 9) samples
showed mild to moderate nuclear expression of EGFR (see
Table 1 and Fig. 5). None of the tumors analyzed harbor
KRAS or EGFR mutations (data not shown). Since clinical
response was not observed in the previously reported phase
II study [5], correlation between immunohistochemical
results and clinical response was not performed.
Discussion
In this study, gefitinib was found to inhibit cell growth and
invasion, induce apoptosis and G1 cycle arrest in human
µ
Fig. 2 Gefitinib (at IC50 concentration) inhibited NPC cell invasion
through the Matrigel
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NPC cell lines, as consistent with previous reports in other
cancer types [9, 10]. However, the relatively high concen-
trations required to achieve these effects suggested that
most NPC cell lines are intrinsically resistant to gefitinib,
with the exception of HK1. Furthermore, treatment with
gefitinib at IC50 concentrations significantly inhibited EGF-
induced phosphorylation of important downstream media-
tors of EGFR, namely, STAT3 and MAPK to a similar
extent in both HK1 and HONE-1 cells, but AKT activation
appeared to remain persistent in both cell lines at similar
concentration. These results prompted the need to elucidate
the molecular basis of these changes by evaluating the
activation level of EGFR and its downstream signaling
mediators, ligand expression, presence of EGFR mutations
and gene amplifications in NPC, by comparing these
molecular profiles between a representative gefitinib-
sensitive (HK1) and a resistant cell line (HONE-1).
The 2 cell lines differed in the basal activation level of
EGFR and downstream mediators, in that HK1 cells
expressed a higher level of p-EGFR and p-MAPK, while
HONE-1 expressed a higher level of p-AKT and p-STAT3.
However, MAPK, AKT and STAT3 activation were similar
in both cell lines under EGF-stimulated condition, suggest-
ing that these signaling axes are inherently intact. Previous
studies in other cancer types have associated resistance to
gefitinib with increased level of MAPK (e.g. prostate
Fig. 3 a Basal expression of activated and total EGFR and its
downstream mediators in NPC cell lines (serum-starved condition). b
Expression of downstream mediators of EGFR in HK1 and HONE-1
at basal, serum-starved, EGF-stimulated (20 ng/ml) and above-IC50
concentration of gefitinib (Iressa®). c Expression of downstream
mediators of EGFR in HK1 (250 nM) and HONE-1 (15 μM) at or
near IC50 concentration of gefitinib. d Expression of EGFR ligands in
NPC cell lines
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cancer cells) [11] and AKT (e.g. in lung [12] and glioma
cells [13]. As consistent with our study, increased STAT3
activation can be found in gefitinib-resistant glioma cells,
despite the fact that STAT3 could be easily inhibited at low
doses of gefitinib [13]. As in our NPC cell lines, higher
concentrations of gefitinib was required to inhibit AKT and
MAPK activation compared with EGFR in gefitinib-
resistant glioma cells, suggesting that the AKT signaling
maybe an escape mechanism for the inhibitory effect of
gefitinib [13].
EGFR was found to be amplified in the gefitinib-sensitive
HK1 cell lines. Gain in gene copy number or EGFR gene
amplification is a common event in NPC, and further
validation is needed to elucidate whether EGFR amplifica-
Fig. 4 High level of EGFR gene amplification was detected in HK1 by aCGH microarray. A high density oligonucleotide aCGH platform with
236,000 features with an average spatial resolution of ~6.4 kB was used. (Agilent’s 244K Human Genome CGH microarray)
Table 1 Immunohistochemical analysis of NPC samples
Patient Tissue type pAKT-ser473 staining EGFR-Tyr 992 (cytoplasmic) staining EGFR-Tyr 845 (Nuclear) staining
1 NP Neg Neg Neg
2 NP Neg 2+ 2+
3 NP Neg 1+ 1+
4 Lung metastasis Neg Neg 1+
5 Lung metastasis 1+ 1+ Neg
6 NP Neg Neg 2+
7 NP 1+ Neg 2+
8 Nodal metastasis 1+ 3+ Neg
9 NP Neg Neg 3+
NP primary nasopharyngeal tumor
Neg negative staining
NA not available
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tion may contribute to the enhanced sensitivity towards
gefitinib in NPC [14]. This is supported by studies in lung
cancer samples, where increased copy number of EGFR has
been associated with better response to gefitinib [15].
Increased expression of EGFR-related ligands have been
shown to predict resistance to EGFR TK inhibitors in vitro,
these include overexpression of TGF-α in breast and
pancreatic cancer cells [16, 17], and amphiregulin in breast
and lung cancer cells [16, 18]. In gefitinib-resistant breast
cancer cells, exposure to gefitinib led to increased nucleo-
cytoplasmic trafficking of EGFR ligands, thereby suggest-
ing the presence of an intracrine feedback loop [16].
However, the current study did not identify any differences
in expression of EGFR ligands between HK1 and HONE-1
cell lines, thus excluding the possibility that reduced basal
activation of STAT3 and AKT in HK1 cells might be
related to altered autocrine signaling in NPC.
Our in vitro data suggests that resistance to gefitinib may
be associated with lower level of EGFR activation and
persistent AKT activation in NPC cell lines, therefore we
examined tumor samples obtained from gefitinib-resistant
participants of a previously reported phase II study [5]. The
study was terminated after 15 patients were entered because
no clinical response was observed, hence the small number
of biopsies obtained for the current study. Around 33%
(3/ 9 samples) of tumors weakly expressed p-AKT, which
concurred with the reported 40% p-AKT overexpresssion
rate in previous reports [19, 20]. Over 50% (5/9 samples) of
the current cohort showed no cytoplasmic EGFR expres-
sion, while over 60% expressed moderate to strong nuclear
EGFR expression—the latter which is a negative prognostic
factor in some cancers [21]. This was unexpected as our
previous report found that over 80% of NPC overexpressed
cytoplasmic EGFR [2]. However, the small number of
tumor samples available makes it difficult to draw
conclusions. The low level of AKT activation in NPC
tumors from gefitinib-resistant patients is consistent with
previous studies in lung cancer, where the lack of p-AKT
expression was associated with poorer clinical outcome
following gefitinib [12, 22].
In summary, a high level of basal EGFR activation
(possibly from EGFR gene amplification) is an important
indicator for sensitivity to gefitinib, while further studies
are needed to confirm whether persistent AKT activation
maybe associated with resistance. Tumoral status of EGFR
activation and gene amplification should be further evalu-
Fig. 5 Immunohistochemical staining for phosphorylated (p-) EGFR
and p-AKT-ser473 in NPC samples. a & d. Immunohistochemical,
IHC. staining for EGFR-Tyr845. a Representative image showing
strong nuclear (grade 3) positivity (case 10, original magnification,
Mag. × 200). d A case with negative staining (case 3, original mag. ×
200). b & e IHC staining for EGFR-Tyr992. b Representative image
showing strong cytoplasmic (grade 3) positivity (case 9, original
Mag. × 200). e A case with negative staining (case 3, original mag. ×
200). c & f IHC staining for pAKT-ser473. c Representative image
showing grade 1 positivity (case 9, original mag. × 200). f A case with
negative staining (case 5, original mag. × 200)
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ated as biomarkers for selecting patients in clinical trials
involving EGFR inhibitors.
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